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Mesp1 is regarded as the master regulator of cardio-
vascular development, initiating the cardiac tran-
scription factor cascade to direct the generation of
cardiac mesoderm. To define the early embryonic
cell population that responds to Mesp1, we per-
formed pulse inductions of gene expression over
tight temporal windows following embryonic stem
cell differentiation. Remarkably, instead of promot-
ing cardiac differentiation in the initial wave of meso-
derm, Mesp1 binds to the Tal1 (Scl) +40 kb enhancer
and generates Flk-1+ precursors expressing Etv2
(ER71) and Tal1 that undergo hematopoietic differen-
tiation. The second wave of mesoderm responds to
Mesp1 by differentiating into PDGFRa+ precursors
that undergo cardiac differentiation. Furthermore, in
the absence of serum-derived factors, Mesp1 pro-
motes skeletal myogenic differentiation. Lineage
tracing revealed that the majority of yolk sac and
many adult hematopoietic cells derive from Mesp1+
precursors. Thus, Mesp1 is a context-dependent
determination factor, integrating the stage of differ-
entiation and the signaling environment to specify
different lineage outcomes.
INTRODUCTION
Cardiac cell therapy from pluripotent stem cells has received
intense interest as a possible treatment of heart diseases (Bur-
ridge et al., 2012; Laflamme and Murry, 2011; Ptaszek et al.,
2012). Pluripotent stem cells first differentiate through an
epiblast state, are subsequently restricted to the mesoderm
and patterned to become cardiovascular, and eventually
develop into cardiovascular progenitors and cardiomyocytes.
Muchwork has been donewith the aim of facilitating this process
by employing various signaling pathway modulators (Burridge
et al., 2011; Kattman et al., 2011; Laflamme et al., 2007; Yanget al., 2008). Despite the value of this approach, each pluripotent
stem cell line produces different levels of endogenous cytokines
during differentiation; hence, the reproducibility of methods
across cell lines is low (Bock et al., 2011; Osafune et al., 2008).
Nonetheless, methods to modulate cardiogenic signaling path-
ways all converge on the activation of a core cardiogenic
transcription network (Olson, 2006). Direct regulation of cardiac
transcription factors is therefore a promising strategy for gener-
ating cardiomyocytes.
Several transcription factors have been identified to be essen-
tial to cardiac development (see Olson, 2006). Among them,
Mesp1 is expressed the earliest, at embryonic day 6.5 (E6.5)
along the primitive streak, and marks the cardiac mesodermal
population that gives rise to both the primary and the secondary
heart fields (Saga et al., 1996). Severe cardiac defects are
observed in Mesp1-null embryos, resulting in lethality by E10.5
(Saga et al., 1999). Furthermore, Mesp1;Mesp2 (the homolog
of Mesp1) double-knockout cells fail to contribute to heart devel-
opment (Kitajima et al., 2000). In the embryonic stem cell (ESC)-
embryoid body (EB) system, Mesp1 overexpression was shown
to induce an array of cardiogenic transcription factors and to
promote cardiovascular differentiation at the expense of other
lineages, for example blood (Bondue et al., 2008; David et al.,
2008; Lindsley et al., 2008). These observations were interpreted
to mean that Mesp1 is responsible for specifying a cardiovascu-
lar fate within the mesoderm by acting as a master regulator at
the apex of a hierarchy of cardiac transcription factors. It is
thus interesting that in the context of reprogramming fibroblasts
into cardiomyocytes, Mesp1 is entirely dispensable (Ieda et al.,
2010). Asmentioned above, distinct cell populations arise during
ESC-EB differentiation in a temporally regulated manner, and
they react diversely to endogenous and exogenous cues. How-
ever, in previous overexpression studies (Bondue et al., 2008;
David et al., 2008; Lindsley et al., 2008), Mesp1 was induced
either constitutively or over a prolonged period of time. Hence,
the cell population that undergoes cardiac differentiation upon
Mesp1 induction remains undefined, and the possibility that
different cell populations may respond differently to Mesp1 in
different contexts has not been addressed.
In order to better define the role ofMesp1 in promoting cardiac
differentiation, we undertook a temporal induction study in whichCell Stem Cell 12, 587–601, May 2, 2013 ª2013 Elsevier Inc. 587
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Figure 1. Opposing Outcomes of Early versus Late Induction of Mesp1
(A and B) Quantitative RT-PCR (n = 3) (A) and immunoblot (B) showing Mesp1 induction by Dox. mRNA, messenger RNA.
(C) Immunoblot demonstrating that Mesp1 induction is tightly regulated by Dox.
(D–H) FACS profile (D) and quantification (E–H) of mesodermal (Flk-1 and PDGFRa), hematopoietic (c-Kit and CD41; c-Kit and CD45), and cardiac (cTnT) markers
during EB differentiation. Dox (500 ng/ml) was applied over 24 hr as indicated by red boxes. (E) The late 24 hr pulse of Mesp1 induction from days 3–4 increased
(legend continued on next page)
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Redefining the Role of Mesp1 in Cardiogenesisdifferentiating ESC progeny were exposed to Mesp1 for short
time windows and in different signaling environments. We
demonstrate in vitro that responsiveness of cells to Mesp1 is
determined in a context-dependent manner, and that the spec-
trum of outputs includes hematopoietic and skeletal myogenic
differentiation. Mesp1-Cre lineage tracing in embryos and adults
reveals that, indeed, the majority of yolk sac hematopoietic cells
and large fractions of both the adult hematopoietic stem cell pool
and the adult skeletal muscle satellite cell pool derive from
Mesp1-expressing precursors. We further show that Mesp1-
marked adult bone marrow cells and satellite cells are trans-
plantable and differentiate into multiple hematopoietic lineages
and muscle fibers, respectively. Our results thus redefine the
role of Mesp1 as a context-dependent coregulator of at least
three types of mesoderm, namely cardiac, hematopoietic, and
skeletal myogenic.
RESULTS
Temporal Mapping Reveals Hematopoietic and
Cardiogenic Mesp1-Responsive Windows
Mesp1 has been reported to act as a master regulator of cardio-
vascular specification, and its overexpression over several days
of EB differentiation increases cardiomyocyte production in vitro
(Bondue et al., 2008, 2011; David et al., 2008; Lindsley et al.,
2008). However, in development, Mesp1 expression is extremely
transient and is restricted primarily to cells within and immedi-
ately egressing from the primitive streak (Saga et al., 1999). To
elucidate the key cell population that responds to Mesp1, we
generated a mouse ESC line in which Mesp1 can be induced
by doxycycline (Dox) (Figures 1A and 1B). In contrast to previous
reports (Bondue et al., 2008; Lindsley et al., 2008), we made use
of a second-generation tetracycline-responsive element (Agha-
Mohammadi et al., 2004) that minimizes leakiness and allows
tighter regulation of Mesp1 expression (Figure 1C). We applied
24 hr pulses of Dox over the course of EB differentiation (except
for the first 2 days, during which we employed a 48 hr pulse) to
determine the optimal time frame for generating cardiomyo-
cytes. The EB consists of continually evolving cell populations:
epiblast cells form by day 2 (i.e., within 48 hr—EB formation is
considered day 0), the first mesoderm forms shortly thereafter,
and lineage-committed cells form on day 4 and beyond (Ismailo-
glu et al., 2008; Keller et al., 1993). Unexpectedly, we observed
opposite outcomes in an early (day 2–3/48–72 hr) pulse of
Mesp1 induction versus a later (day 3–4/72–96 hr) pulse (Fig-
ure 1D; Figures S1A–S1C available online).
The late 24 hr pulse of Mesp1 induction from day 3, corre-
sponding to the window in which cardiovascular mesoderm is
normally specified (Kattman et al., 2006; Kouskoff et al., 2005),
produced the anticipated increases in both Flk-1+PDGFRa+
cells, the presumptive cardiac mesoderm population at day 4,
and cTnT+ (cardiac troponin T) cardiomyocytes by day 8 (Figures
1D and 1E).Flk-1+PDGFRa+ presumptive cardiac mesoderm at day 4 (left, n = 15) and cTnT
induction from days 2–3 promoted Flk-1+PDGFRa+ presumptive early unpattern
plate mesoderm at day 4 (right, n = 10). (G and H) Mesp1 day 2–3 induction
c-Kit+CD41+ (G, left, n = 10), c-Kit+CD45+ (G, right, n = 8), c-Kit–CD41+ (H, left
Mean ± SEM is shown in (A) and (E)–(H). *p < 0.05; **p < 0.01; ***p < 0.001 versuA 24 hr pulse of Mesp1 induction in the earlier window (from
day 2) also had dramatic effects on mesoderm formation. Pre-
sumptive early unpatterned mesoderm, the Flk-1+PDGFRa+
population at day 3.25, and presumptive lateral plate meso-
derm, the Flk-1+PDGFRa– population at day 4, were increased
by 3-fold and 2-fold, respectively (Figures 1D and 1F). In con-
trast to the late pulse, this early pulse of Mesp1 did not increase
cardiomyocyte production at day 8 (Figure 1D, bottom row).
Rather, this early Mesp1 pulse unexpectedly increased hemato-
poietic progenitor populations c-Kit+CD41+ and c-Kit+CD45+
by 3- and 7-fold, respectively, at day 6 (Figures 1D and 1G).
More-differentiated hematopoietic cells, including c-Kit–CD41+
and c-Kit–CD45+, were also elevated (by 2- and 13-fold,
respectively; Figures 1D and 1H). The different phenotypes
produced by the early and late pulses of Mesp1 probably are
not a direct consequence of variable Mesp1 dosages, given
that similar levels of Mesp1 were induced in both windows
(Figure S1D).
We next investigated whether Flk-1 and PDGFRa are direct
targets of Mesp1, which may explain the rapid generation of
Flk-1+ and PDGFRa+ cells. EBs cultured in the absence of
serumdo not express Flk-1 or PDGFRa (Figure S1E, left column).
Upon Mesp1 induction from day 3, PDGFRa+ cells appeared
within 6 hr (day 3.25) and were greatly increased in 24 hr
(day 4), but all cells remained Flk-1– (Figure S1E, left column).
These results, as well as chromatin immunoprecipitation (ChIP)
of Mesp1 on Pdgfra (Figures S1F and S1G), suggest PDGFRa,
but not Flk-1, as a potential direct target of Mesp1.
The unanticipated hematopoiesis contrasts with previous
work (Bondue et al., 2008; Lindsley et al., 2008), in which hema-
topoiesis was inhibited by Mesp1 induction. However, those
studies used an extended period of Mesp1 induction, whereas
the 24 hr pulses used here more closely approximate the tran-
sient pattern of Mesp1 expression in the embryo (Saga et al.,
1999). Therefore, our results suggest that instead of solely spec-
ifying cardiovascular mesoderm, Mesp1 has distinct effects in
different cell populations, and its cardiogenic and prohemato-
poietic effects occur in temporally separate windows.
Fully Differentiated Hematopoietic Cells and
Cardiomyocytes Specified by Early or Late Pulses of
Mesp1
To further characterize the differentiation outputs of the two
Mesp1 induction windows, we measured the expression levels
of key genes specific to these two lineages at day 6 (Figure 2A).
We observed significant upregulation of hematopoiesis-specific
genes—such as Gata1, Sfpi1 (PU.1), Runx1, and Hbb-bh1—by
the early pulse, but not by the late pulse. In contrast, the late
pulse upregulated cardiac-specific markers, including Myl7
(Mlc-2a), Myl2 (Mlc-2v), Tnnt2 (cTnT), and Tnni3 (cTnI), whereas
the early pulse did not. At the protein level, the late pulse
of Mesp1 elevated the expression of Nkx2.5, a cardiogenic
transcription factor, and downstream markers cTnT, cTnI, and+ cardiomyocytes at day 8 (right, n = 15). (F) The early 24 hr pulse of Mesp1
ed mesoderm at day 3.25 (left, n = 5) and Flk-1+PDGFRa– presumptive lateral
increased several hematopoietic progenitor populations at day 6, including
, n = 10), and c-Kit–CD45+ (H, right, n = 8).
s No Dox. See also Figure S1.
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Figure 2. Characterization of Differentiated Cell Types Promoted by Mesp1 in Early or Late Mesoderm
(A) Quantitative RT-PCR for hematopoietic- and cardiac-specific markers for day 6 EBs (n = 3). Note that the early pulse (day 2–3) of Mesp1 induction (green bars)
upregulated hematopoiesis-specific markers, but not cardiac-specific markers (versus No Dox, gray bars), whereas the late pulse (day 3–4, red bars) did the
opposite.
(B) Immunoblot demonstrating the upregulation of cardiac-specific proteins in day 8 EBs subjected to the late pulse of Mesp1 induction.
(C) Immunostaining for cTnT (green) or a-actinin (green) and CX43 (red) in Mesp1-induced EB-derived cardiac cells.
(D) Hematopoietic colonies induced byMesp1 (left) and quantification (right, n = 3–6). Note that the early pulse of Mesp1 induction increased the numbers of both
primitive (Ery-P) and definitive (Ery-D, GM, GEMM, and Mac) hematopoietic cell types.
(E) Scheme for determining cell autonomy of Mesp1-induced hematopoiesis (left) and FACS analysis of hematopoietic markers (c-Kit and CD41) in day 6 EBs
(right). Note that both c-Kit+CD41+ progenitors and c-Kit–CD41+ differentiated cells were increased in the GFP– population, but neither was increased in the
GFP+ population, suggesting that Mesp1 induction of hematopoiesis is cell autonomous.
Ery-P, primitive erythroid; Ery-D, definitive erythroid; GM, granulocyte-macrophage; GEMM, granulocyte-erythrocyte-megakaryocyte-macrophage; Mac,
macrophage. Mean ± SEM is shown in (A) and (D). *p < 0.05; **p < 0.01; ***p < 0.001 versus No Dox. See also Figure S2.
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Redefining the Role of Mesp1 in Cardiogenesissarcomeric a-actinin (Figure 2B). Furthermore, after plating on
adherent surfaces, adjacent Mesp1-induced ESC-derived cardi-
omyocytes exhibited synchronous contractions and expressed
the gap-junction protein connexin 43 (CX43) at cell-cell inter-
faces, indicating electrical coupling (Figure 2C). These data are590 Cell Stem Cell 12, 587–601, May 2, 2013 ª2013 Elsevier Inc.all consistent with a later window of Mesp1 induction driving car-
diac specification.
Considering that PDGFRa is a potential target of Mesp1
and that the early pulse of Mesp1 appears to promote the
Flk-1+PDGFRa+ population at day 4 without inducing cardiac
Cell Stem Cell
Redefining the Role of Mesp1 in Cardiogenesisdifferentiation (Figure 1D, second and bottom rows), we wished
to investigate the cardiogenic potential of day 4 Flk-1+PDGFRa+
cells. Supporting our previous observation, day 4 sorted Flk-
1+PDGFRa+ cells previously subjected to the late pulse of
Mesp1 exhibited an upregulation of cardiac genes (Myl7,
Myl2, Tnnt2, and Tnni3) after 4 days of additional culture in
cardiogenic medium (Figure S2A). Immunostaining further
showed that the Flk-1+PDGFRa+ fraction, in contrast to the
Flk-1–PDGFRa– fraction, is enriched in generating cTnT+ cardi-
omyocytes (Figure S2B).
To confirm that the early pulse of Mesp1 indeed promotes
hematopoiesis, we performed colony-forming assays. The early
Mesp1 pulse resulted in a 2- to 5-fold increase in all types of
hematopoietic colonies assayed (Figure 2D), demonstrating
that Mesp1 induction during early mesoderm specification pro-
motes both the first wave of primitive erythroiesis and later multi-
lineage hematopoiesis.
Mesp1 Acts Cell Autonomously in Inducing
Hematopoietic Differentiation
Mesp1 has been shown to act cell autonomously in inducing car-
diomyocyte differentiation (Bondue et al., 2008). To determine
whether Mesp1 acted cell autonomously in promoting hemato-
poiesis, we generated chimeric EBs by mixing the inducible
Mesp1 (iMesp1) ESCs with wild-type, GFP-labeled ESCs (E14-
GFP) at defined ratios and provided a hematopoiesis-inducing
pulse of Mesp1 at day 2 (Figure 2E, left panel). We observed in-
creases in CD41+ cells in the GFP– (iMesp1) fraction only (Fig-
ure 2E, right panel). These data strongly suggest that the early
pulse of Mesp1 promotes hematopoiesis specifically in those
cells that express Mesp1—that is, in a cell-autonomous fashion.
Mesp1 Induces Hematopoiesis via Regulation of Etv2
and Tal1
As discussed above, Mesp1 produced distinct mesoderm pop-
ulations at different stages of EB development (Figure 1D) and
generated different lineage-specific gene-expression signatures
(Figure 2A). Consequently, we profiled temporal expression pat-
terns of major prohematopoietic and cardiogenic transcription
factors and discovered that the two Mesp1-induction windows
activated discrete mesoderm-patterning programs. In unstimu-
lated cells, Etv2 (ER71) and Tal1 (Scl), two critical modulators
of hematopoietic and endothelial specification (Ferdous et al.,
2009; Kallianpur et al., 1994; Lee et al., 2008; Robb et al.,
1995; Shivdasani et al., 1995), showed the strongest expression
between days 3.25 and 4 and gradually decreased thereafter
(Figure 3A, gray lines). The early Mesp1 pulse accelerated this
process by markedly inducing Etv2 (13-fold) and Tal1 (22-fold)
at as early as day 3.25 (Figure 3A, green lines). Other prohema-
topoietic transcription factors such as Gata2, Lmo2, and Runx1
were also increased by early Mesp1 induction (Figure S3A). Etv2
has been suggested to be expressed by some Mesp1+ cells
(Bondue et al., 2008, 2011), whereas Tal1 is not reported to be
a direct target of Mesp1. The elevated Tal1 expression at day
3.25–4 is particularly interesting, because 24 hr pulses of Tal1
induction were shown to produce phenotypes very similar to
what we have observed from the early pulse of Mesp1: dramatic
increases in Flk-1+PDGFRa– presumptive lateral plate meso-
dermal cells at day 4 and c-Kit+CD41+ and CD45+ hematopoi-etic progenitors at day 6 (Ismailoglu et al., 2008). Overexpression
of Etv2 produces similar phenotypes (Koyano-Nakagawa et al.,
2012). Therefore, coordinate upregulation of Etv2 and Tal1 prob-
ably explains the prohematopoietic effects of the early pulse of
Mesp1 expression.
Mesp1 Dimerizes with E12 to Bind to the Tal1 +40 kb
Enhancer
Several Tal1 enhancers have been identified, but only the +40 kb
enhancer region contains E-box motifs (Ogilvy et al., 2007),
potential binding sites for Mesp1 (Figure 3B, left panel). We per-
formed ChIP in day 3 EBs after a prior 24 hr Mesp1 pulse and
found that Mesp1 was enriched at this cis-regulatory element
(Figure 3B, right panel) with a concurrent upregulation of Tal1
expression (Figure S3B). We further verified this interaction by
testing a Gal4-Mesp1 fusion for transcriptional activity and found
that it is a transactivator in multiple cell types (Figure S3C).
We next performed electrophoretic mobility shift assays to
confirm the direct interaction between Mesp1 and the Tal1 +40
kb enhancer. As is typical for a class I basic-helix-loop-helix
(bHLH) factor, Mesp1 by itself did not bind to the E-box motif
of the Tal1 +40 kb enhancer (Figure 3C, left). However, upon het-
erodimerization with E12 (an isoform of E2A), Mesp1 could bind
to the Tal1 E-box motif (Figure 3C, right). E12 alone did not bind
(Figure 3C, middle). Mesp1-E12 binding was further verified by
its reduction by a wild-type competitor, but not an E-box-motif
mutant, and the presence of a supershift signal (Figure 3C, right).
Mesp1-Expressing Progenitors Contribute to Both
Embryonic and Adult Hematopoiesis In Vivo
The results above are entirely in vitro, and previous Mesp1-Cre
lineage-tracing experiments indicated that Mesp1+ precursors
do not contribute to adult hematopoiesis (Lindsley et al., 2008).
Because the ESC-EB system recapitulates yolk sac hematopoi-
esis, we reasoned that the prohematopoietic effects of Mesp1
may have been restricted to transient early yolk sac hematopoi-
esis, which had not previously been evaluated. We crossed the
Mesp1-Cre mice (Mesp1Cre/+) with a floxed-stop lacZ reporter
line (R26fl-stop-lacZ/fl-stop-lacZ) to trace the progeny of Mesp1-
expressing cells during embryogenesis. At E9.5, Mesp1Cre/+;
R26fl-stop-lacZ/+ embryos showed extensive lacZ staining in the
heart (Figure 4A) as expected (Saga et al., 1999). Remarkably,
most hematopoietic cells inside the heart chamber were also
positive for lacZ (Figure 4A, white arrowheads). In the yolk sac,
the majority of hematopoietic cells in the blood islands were
lacZ+, as were the underlying endothelial cells, but not the
yolk sac endoderm (Figure 4A, white arrowheads). Moreover,
some lacZ+ cells were also visible in the aortic endothelium of
the aorta-gonad-mesonephros (AGM) region (Figure 4A, white
arrowheads). To quantify this phenomenon, we further crossed
the Mesp1Cre/+ mice with a fluorescent floxed-stop reporter
line (R26fl-stop-EYFP/fl-stop-EYFP) and performed fluorescence-acti-
vated cell sorting (FACS) analysis. Evaluation of E9.5 yolk sacs
and embryos revealed that a majority of Ter119+ primitive
erythroid cells, CD41+ hematopoietic progenitor cells, and
Flk-1+ endothelial cells in both yolk sacs and embryos were
EYFP+ (Figures 4B and 4D). These observations thus imply
that Mesp1-expressing precursors contribute extensively to
embryonic hematopoiesis.Cell Stem Cell 12, 587–601, May 2, 2013 ª2013 Elsevier Inc. 591
Figure 3. Mesp1 Promotes Hematopoiesis by Regulating Etv2 and Tal1
(A) Quantitative RT-PCR for regulatory hematopoietic and cardiogenic transcription factors during EB differentiation (n = 3). Note that EBs treated with the early
Mesp1 pulse (green line) rapidly upregulated hematopoietic transcription factors Etv2 and Tal1 at day 3.25 (versus No Dox, gray line), and Tal1 continued to be
elevated by day 4, but expression levels fell back to or below the control (No Dox) level by day 6. On the other hand, the late pulse of Mesp1 (red line) led to a
gradual and sustained upregulation of cardiogenic transcription factors Gata4, Tbx5, and Nkx2-5 from day 4 to day 6.
(B) Schematic showing the +40 kb enhancer of Tal1 and the E-box motifs therein (left). The relative locations of a nearby gene, Pdzk1ip1 (Map17), and the primer
set for PCRdetection are also shown. ChIP analysis of day 3 EBs (right, n = 3) illustrates thatMesp1 binds to this Tal1 cis-regulatory element.Gapdhwas used as a
control.
(C) Electrophoretic mobility shift assay analysis showing that neither Mesp1 (left) nor its cofactor E12 (an isoform of E2A) (middle) alone bound to the E-boxes of
the Tal1 +40 kb enhancer (left), but their dimerization complex could have done so (right). The specific binding and the supershift signal are indicated by the
arrowhead and the star, respectively. ctrl, control (cell lysate from empty vector for lane 2 and immunoglobulin G (IgG) antibody for lane 6); mut, mutant (E-box
motif mutant competitor); WT, wild-type (wild-type competitor).
Mean ± SEM is shown in (A) and (B). *p < 0.05; **p < 0.01; ***p < 0.001 versus No Dox. See also Figure S3.
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itive hematopoiesis. The contribution of the yolk sac to the adult
hematopoietic system remains controversial (Cumano et al.,
1996, 2001; Huang and Auerbach, 1993; Lux et al., 2008; Med-
vinsky and Dzierzak, 1996; Palis et al., 1999; Samokhvalov592 Cell Stem Cell 12, 587–601, May 2, 2013 ª2013 Elsevier Inc.et al., 2007). To evaluate whether Mesp1+ progenitors are
restricted to yolk sac hematopoiesis, we analyzed the labeling
of different hematopoietic lineages in 6-week-old mice from
the same crosses. FACS analysis of the thymus, spleen, and
bone marrow of these animals revealed considerable EYFP
Cell Stem Cell
Redefining the Role of Mesp1 in Cardiogenesisexpression in all hematopoietic populations examined in the
thymus, spleen, and bone marrow (Figures 4C and 4D and
Figures S4A–S4C). Most importantly, the bone marrow hemato-
poietic stem cell compartment (Lin–Sca-1+c-Kit+) was 30%
EYFP+ (Figure 4C, far right, and Figure 4D).
Mesp1+ Bone Marrow Cells Repopulate the
Hematopoietic Compartment of Irradiated Hosts
To conclusively demonstrate that Mesp1-marked bone marrow
contained hematopoietic stem cells, we sorted the EYFP+ frac-
tion from total bone marrow cells of Mesp1Cre/+;R26fl-stop-EYFP/+
animals and transplanted it into irradiated NSG-CD45.1/CD45.1
recipient mice. The NSG-CD45.1/CD45.1 mice were homozy-
gous for the CD45.1 allele, thus facilitating simultaneous
analysis of host (CD45.1+) or donor (CD45.2+)-derived hemato-
poietic cells. Remarkably, the peripheral blood of recipients
was mostly donor derived at 4 weeks (5/5, 89% ± 7% chime-
rism), 8 weeks (4/4, 96% ± 2% chimerism), and 4 months
(4/4, 96% ± 4% chimerism) in every lineage examined (Fig-
ure 4E, top row). By transplanting Mesp1-unlabeled (EYFP–
CD45.2+) bone marrow cells, we further demonstrated that
Mesp1 was not re-expressed in the adult hematopoietic sys-
tem, in that there were no EYFP+ cells in the peripheral blood
(Figure 4E, bottom row). Therefore, our data provide clear
evidence that Mesp1+ precursors contribute to both embryonic
and adult hematopoiesis and, by correlation, that Mesp1
expression per se does not inhibit hematopoiesis in vivo, as
previously suggested.
Mesp1 Is Necessary for Normal Yolk Sac Hematopoiesis
To address whether Mesp1 is required for yolk sac hematopoi-
etic development, we took advantage of the fact that Mesp1-
Cre is a null allele (Saga et al., 1999).We intercrossedMesp1Cre/+
mice to generate Mesp1Cre/Cre mice, which have no functional
Mesp1. Mesp1Cre/Cre animals had severe cardiac defects and
did not survive beyond E10.5 (our observation and Saga et al.,
1999). Because fluid shear stress is known to regulate embryonic
hematopoiesis (Adamo et al., 2009; North et al., 2009), we
analyzed the Mesp1Cre/Cre embryos at E8.25–E8.5 (six to eight
somite pairs) prior to circulation to avoid secondary effects
from blood flow. Using the colony-forming assay, we observed
that the yolk sacs of Mesp1Cre/Cre embryos produced signifi-
cantly fewer hematopoietic colonies than those of Mesp1+/+
andMesp1Cre/+ embryos (Figure 4F). Therefore, Mesp1 is neces-
sary for normal yolk sac hematopoiesis.
Mesp1 Promotes Paraxial Mesoderm and Myogenic
Derivatives in the Absence of Serum-Derived Factors
Mesp1 is known to label the craniofacial mesodermal popula-
tion that develops into the cranial musculature (Harel et al.,
2009; Saga et al., 1999, 2000), but Mesp1 has not been demon-
strated to induce cranial myogenesis in ESCs, and indeed, skel-
etal myogenesis is notoriously absent in conventional ESC-EB
differentiation (Darabi et al., 2008). Because serum-derived fac-
tors are required for both hematopoietic and cardiac differenti-
ation, we investigated what effect Mesp1 induction would have
in the absence of serum (Figure 5A). Mesoderm formation is
abolished in EBs grown in the absence of serum, as indicated
by a lack of Flk-1+ or PDGFRa+ cells in day 5 EBs (Figure 5B).However, continuous Mesp1 induction from day 3 promoted
the emergence of Flk-1–PDGFRa+ cells, suggesting a presump-
tive paraxial mesoderm population (Darabi et al., 2008; Sakurai
et al., 2006) (Figure 5B). Further gene-expression characteriza-
tion of Mesp1-induced cells showed that Mesp1 induction from
days 3–8 led to the upregulation of paraxial and presomitic
mesodermal genes, including Meox1, Tcf15 (paraxis), Msgn1
(mesogenin), and Mesp2 (Figure 5C, top row). Panmyogenic
genes such as Myf5, Myod1 (MyoD), Myog (myogenin), and
Mef2c and myogenic genes pertaining to craniofacial and
pharyngeal muscles such as Tbx1 and Pitx2 were also upregu-
lated (Figure 5C, middle and bottom rows). Interestingly, these
myogenic genes remained elevated for at least 4 days after
Dox removal (assayed at day 12; Figure 5C, middle and bottom
rows), indicating that Mesp1 promoted the initiation of, but
was dispensable for the maintenance of, the skeletal myogenic
program. Immunoblotting further verified that Mesp1 induction
promoted the generation of skeletal myogenic progenitors,
as demonstrated by the presence of MyoD, myogenin, and
M-cadherin (Figure 5D). Immunohistochemistry indicated the
presence of myoblasts, characterized as MyoD+, myogenin+,
sarcomeric myosin heavy chain (MHC)+ (Figure 5E), and multi-
nucleated MHC+ myotubes under conditions of differentiation
(Figure 5F). Thus, we have demonstrated that an extended win-
dow of late Mesp1 induction in the absence of serum-derived
factors promotes paraxial mesoderm and myogenic derivatives
from ESCs.
Mesp1-Expressing Precursors Give Rise to Satellite
Cells of Craniofacial Skeletal Muscles
Based on these in vitro results, we next examined the relative
contribution of Mesp1-expressing progenitors in cranial and
trunk myogenesis, identifying satellite cells as Lin–(CD31– and
CD45–)a7-integrin+CD34+ or Lin–a7-integrin+VCAM-1+ (Biressi
and Rando, 2010). We further verified these gating strategies
(Figure 6A) using Pax7-ZsGreen mice in which all satellite
cells are ZsGreen+ (Bosnakovski et al., 2008). Satellite cells
from six different muscle groups (facial, masseter, diaphragm,
triceps, back, and hindlimb muscles) of adult Mesp1Cre/+;
R26fl-stop-YFP/+ mice were analyzed by using FACS for enhanced
yellow fluorescent protein (EYFP) expression (Figures 6B and
S5). Satellite cell populations in facial and masseter muscles
that are of craniofacial mesodermal origin were mainly EYFP+
(73% in the facial muscles and 76% in the masseter, Figure 6B
far- and middle-left panels, and Figure 6C). The diaphragm,
potentially of mixed origin of both trunk paraxial and cranial
splanchnic mesoderm (Ackerman and Greer, 2007), contained
a small but obvious and reproducible fraction of EYFP+ satellite
cells (12%, Figure 6B, middle-right panels, and Figure 6C). In
contrast, hindlimb- and trunk-derived satellite cells rarely coex-
pressed EYFP (3% in both muscles, Figure 6B, far-right panels,
and Figure 6C). To confirm the skeletal myogenic potential of
the Mesp1-marked prospectively isolated satellite cells, we
cultured them under myogenic differentiation conditions (Bos-
nakovski et al., 2008). Sarcomeric MHC+myotubes were readily
observed in all samples (Figure 6D). These results therefore
demonstrate that Mesp1 induction of skeletal myogenesis
is physiologically significant, particularly to anterior muscle
groups.Cell Stem Cell 12, 587–601, May 2, 2013 ª2013 Elsevier Inc. 593
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Figure 4. Mesp1 Marks Progenitors that Contribute to Both Embryonic and Adult Hematopoiesis
(A) Whole-mount lacZ staining of Mesp1Cre/+;R26fl-stop-lacZ/+ E9.5 embryos and yolk sacs and sections thereof. Note that lacZ staining was observed in cells of
mesodermal origin, but not cells in the neural crest or in the yolk sac endodermal layer. In particular, lacZ+ blood cells (white arrowheads) were found within the
heart chambers, the AGM region, and the yolk sac blood islands. The scale bar represents 500 mm (upper left) or 100 mm (others).
(B) FACS profiles of hematopoietic (Ter119 and CD41) and endothelial (Flk-1) markers in Mesp1Cre/+;R26fl-stop-EYFP/+ E9.5 yolk sacs (top row) and embryos
(bottom row).
(C) FACS profiles of hematopoietic markers in the thymus (far-left panels), the spleen (middle-left panels), and the bone marrow (middle- and far-right panels) of
adult Mesp1Cre/+;R26fl-stop-EYFP/+ animals.
(D) Quantification of EYFP expression by FACS in hematopoietic fractions of various origins in E9.5 and adult Mesp1Cre/+;R26fl-stop-EYFP/+ animals (n = 5–7). Note
that all hematopoietic lineages examined contain a significant EYFP+ fraction.
(E) Mesp1-marked bone marrow cells repopulated and contributed to multiple hematopoietic lineages. EYFP+ (top row) and EYFP– (bottom row) total bone
marrow cells from adult Mesp1Cre/+;R26fl-stop-EYFP/+ animals were transplanted to NSG-CD45.1/CD45.1 recipient mice. FACS analysis of the peripheral blood
4 months later showed that almost all blood cells derived from the donor (CD45.2+), not from the host (CD45.1+) (far-left panels). Note that Mesp1-unlabeled
transplanted cells remained EYFP– (bottom row, middle-left panels), indicating that Mesp1 is not re-expressed in the adult hematopoietic system.
(legend continued on next page)
Cell Stem Cell
Redefining the Role of Mesp1 in Cardiogenesis
594 Cell Stem Cell 12, 587–601, May 2, 2013 ª2013 Elsevier Inc.
Cell Stem Cell
Redefining the Role of Mesp1 in CardiogenesisMesp1+ Satellite Cells Engraft and Form Muscle Fibers
in mdx4Cv Mice
To conclusively demonstrate that Mesp1-marked, Lin–a7-
integrin+VCAM-1+ cells were truly muscle stem cells, we
purified and transplanted these cells into immune-deficient, dys-
trophin-deficient NSG-mdx4Cv animals (Arpke et al., 2013) and
used dystrophin staining to identify donor-derived myofibers
in vivo. We transplanted 2,500 and 200 EYFP+ satellite cells
from the masseter and the tibialis anterior (TA), respectively,
into cardiotoxin-injured, irradiated recipient TA muscles. The
lower number of marked cells from the donor TAs reflects the
very low percentage of TA satellite cells that are marked by
Mesp1. Six weeks posttransplant, immunostaining revealed
large clusters of dystrophin+ myofibers in transplanted, but not
control, recipient TAs (Figure 6E), indicating that both the abun-
dant Mesp1-marked satellite cells from the masseter and the
rare Mesp1-marked cells from the TA are bona fide muscle
stem cells.
DISCUSSION
Mesp1 Patterns Mesoderm into Different Fates
Depending on the Stage of Differentiation and the
Signaling Environment
Mesp1hasbeenconsidered the cardiacmaster regulator, driving
cardiovascular specification and inhibiting other mesodermal
lineages (Bondue et al., 2008, 2011; David et al., 2008; Lindsley
et al., 2008). In this report, we challenge this paradigm and pro-
vide evidence that Mesp1 actually patterns the mesoderm into
multiplemesodermal lineages, including cardiac, hematopoietic,
and skeletal muscle, in a context-dependent manner.
Mesp1 is expressed in the nascent mesoderm but is abruptly
downregulated as the newly formed mesoderm migrates out of
the primitive streak (Saga et al., 1999). Mesp1-expressing cells
were found to give rise to all cardiac lineages (Kitajima et al.,
2000; Saga et al., 1999, 2000). Interestingly, some marking
was also observed in extraembryonic mesoderm at early-streak
stage (E6.5–6.75), and Mesp1 was postulated to be expressed
earlier in this mesodermal subpopulation than in cardiac meso-
derm (Saga et al., 1999). By looking at the yolk sac in E9.5
embryos, we show that Mesp1 labels extraembryonic hemato-
poietic and endothelial cells extensively. In line with this ob-
servation, we demonstrate in vitro that Mesp1 can induce
hematopoietic differentiation, and this effect is most pronounced
during a window that slightly precedes that in which Mesp1
drives cardiac differentiation.
In conventional ESC-EB differentiation, mesoderm is postu-
lated to arise in distinct waves, with the first wave contributing
primarily to the hematopoietic and endothelial lineages and the
second contributing to cardiac and endothelial lineages (Irion
et al., 2010; Kattman et al., 2006; Kouskoff et al., 2005). Further
work suggested that the first wave generates a Flk-
1+PDGFRa– presumptive lateral plate mesoderm population,(F) Hematopoietic colony-forming assay showing that yolk sacs of Mesp1Cre/Cre kn
fewer hematopoietic colonies than those of Mesp1+/+ and Mesp1Cre/+ embryos.
BMT, bone marrow transplantation; Lin, lineage cocktail comprising CD3, CD4,
CD45.1/CD45.1, CD45.1/CD45.1 homozygous on the NOD scid gamma backgro
Mean ± SEM is shown in (D). See also Figure S4.whereas the second wave gives rise to an Flk-1+PDGFRa+
presumptive cardiac mesoderm population (Hirata et al., 2007;
Sakurai et al., 2006). It is interesting that we observed similar
temporal specificities of Mesp1 induction in which an early
24 hr pulse (starting at 48 hr) promoted an Flk-1+ population
and hematopoiesis, whereas a later pulse (starting at 72 hr)
promoted a PDGFRa+ population and cardiogenesis. The stage
of differentiation thus governs the responsiveness of cells to
Mesp1.
The patterning activity of Mesp1 is modulated by the signaling
environment. In the absence of serum, Mesp1 induces paraxial
mesoderm that goes on to differentiate into skeletal myogenic
derivatives, remarkable because this lineage is virtually absent
in conventional EB differentiation (Darabi et al., 2008). The
impact of signaling on mesodermal patterning has been exten-
sively studied (Arnold and Robertson, 2009; Tam and Loebel,
2007). As Mesp1-expressing cells leave the primitive streak,
they are subjected to various signaling gradients including
BMP4, known to induce cardiogenesis but inhibit cranial myo-
genesis (Tirosh-Finkel et al., 2006). Our results suggest that
serum-derived factors recapitulate this effect and direct
Mesp1-responsive cells toward the cardiac lineage, whereas
the lack thereof in serum-free conditions leads to paraxial meso-
derm and skeletal myogenic differentiation.
Mesp1 Does Not Invariably Suppress Hematopoiesis
Previous studies have reported that Mesp1 directly suppresses
hematopoiesis in vitro (Bondue et al., 2008, 2011; Lindsley
et al., 2008), and that it is not expressed in the precursors of
the hematopoietic lineage in vivo (Lindsley et al., 2008). How-
ever, the broad distribution of Mesp1-expressing cells in the
yolk sac at its hemogenic prime merits reevaluation of this
assumption. Lineage tracing revealed that a large fraction of
hematopoietic progenitors in embryos and hematopoietic stem
cells in adults is of Mesp1 origin. A larger number of Mesp1-
labeled hematopoietic cells in embryos than in adults may
indicate the emergence of a Mesp1-unlabeled hematopoietic
progenitor population later (>E9.5) during development.
Although our lineage-tracing data in adult mice contradicts that
of a previous report, the two studies used different reporters:
EGFP in the former (Lindsley et al., 2008), versus EYFP, which
generates a more intense fluorescence signal (Shaner et al.,
2005), in the current study. Furthermore, Mesp1 expression is
not merely passively marking hematopoietic progenitors: em-
bryos deficient for Mesp1 suffer a severe reduction in yolk sac
hematopoietic progenitor frequency. It was recently shown
that Mesp1 is required for expression of Meis1 in endothelial
cells derived from ESCs, which is interesting because of the
prohematopoietic effects of Meis1 (Cai et al., 2012). Thus, in
the appropriate context, Mesp1 promotes and is required for
hematopoiesis.
We found that an early pulse of Mesp1 induction transiently
induced the transcription factors Etv2 and Tal1 and resulted inockout embryos (E8.25–E8.5, equivalent to six to eight somite pairs) produced
*p < 0.05.
CD8, Mac1, B220, Gr-1, and Ter119; HSC, hematopoietic stem cells; NSG-
und.
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Figure 5. Mesp1 Promotes Paraxial Mesoderm and Myogenic Derivatives in the Absence of Serum-Derived Factors
(A) Scheme depicting the protocol used to examine the effect of Mesp1 on ESC differentiation in serum-free conditions.
(B) FACS analysis of mesodermal markers Flk-1 and PDGFRa in day 5 EBs grown under serum-free conditions.
(C) Quantitative RT-PCR for various lineage-specific markers in serum-free culture conditions in which Mesp1 was induced from day 3 to day 8 (blue bars) or not
induced (gray bars) (n = 3).
(D) Immunoblot showing upregulation of myogenic proteins upon Mesp1 induction from day 3 to day 8 under serum-free conditions.
(E) Immunostaining for myogenic markers—MyoD (left), Myogenin (middle), and MHC (right)—in EB-derived cells induced by Mesp1 from day 3–8 cultured in the
absence of serum. Areas depicted by the white dotted rectangle are magnified to demonstrate the localization of the nucleus (DAPI) and the nuclear (MyoD and
Myogenin) or cytoplasmic (MHC) markers of interest (bottom panels). No MyoD+, Myogenin+, or MHC+ cells were observed in control (No Dox) wells (data not
shown). The scale bar represents 200 mm.
(legend continued on next page)
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multilineage hematopoietic progenitors by day 6. Importantly,
within this early window, we discovered that Mesp1 directly reg-
ulates the transcription of Tal1, and we identified E12 as a
cofactor that allows binding of Mesp1 to the +40 kb cis-regula-
tory element of Tal1. This interaction is particularly interesting
in light of a recent report demonstrating that in the absence of
Tal1, yolk sac cells can differentiate into cardiomyocytes (Van
Handel et al., 2012). This and previous work (Ismailoglu et al.,
2008) show that the simple presence of Tal1 drives the hemato-
poietic program in cells otherwise fated to become cardiac. The
lineage tracing of Mesp1 to the yolk sac suggests that in the
absence of Tal1, Mesp1 promotes a cardiac program in these
earliest mesodermal cells. It will be interesting to determine
what prevents Mesp1 from activating Tal1 outside of this unique
early window.
Regulation of Mesp1 Is a Developmentally Relevant
Approach to Generating Craniofacial Myogenic
Precursors
Certain muscle disorders manifest differently between the head
and the trunk muscles (Emery, 2002). For instance, Duchenne
muscular dystrophy affects the limb muscles more severely
than it affects those in the head (Duchenne, 1868), whereas in
facioscapulohumeral muscular dystrophy the facial muscles
are almost always profoundly affected, but distal limb muscles
are relatively spared (Landouzy and De´je´rine, 1885). Although
this discrepancy is not fully understood, the cranial muscles
are known to have different muscle fiber-type compositions
(Schiaffino and Reggiani, 2011) and genetic signatures (Bothe
et al., 2011; Bryson-Richardson and Currie, 2008; Shih et al.,
2008) compared to their trunk counterparts. Examination of the
regenerative potentials of satellite cells from different head and
trunk muscle groups revealed that the satellite cells of the
head muscles show different proliferative properties but engraft
equally well in limb muscles (Ono et al., 2010; Sambasivan et al.,
2009). Therefore, deriving craniofacial myogenic precursors may
be useful for studying disease processes specific to these mus-
cles. Considering the substantial contribution of Mesp1+ precur-
sors to the adult head-muscle fibers (Harel et al., 2009) and the
adult muscle stem cell pool (Figures 6B, 6C, and S5), it is
conceivable that Mesp1 plays a key role in activating the skeletal
myogenic program. In fact, our work constitutes a method for
generating skeletal myogenic precursors from ESCs through
Mesp1 induction, a feat previously only accomplished through
Pax3 or Pax7 expression (Darabi et al., 2008, 2011, 2012). These
myogenic precursors can fuse into myotubes and contain
elevated expression of Tbx1 and Pitx2, which are the hallmark
genes of pharyngeal and craniofacial muscles (Sambasivan
et al., 2009). Therefore, Mesp1 induction is a developmentally
relevant approach for deriving craniofacial myogenic precursors
from pluripotent cells.
In this report, we provide evidence that Mesp1 contributes to
the specification of multiple mesoderm lineages in a context-(F) Immunostaining showing the presence of multiple nuclei (white arrowheads) in
blue channel (DAPI) are individually merged with the phase-contrast channel to in
(bottom panels). The scale bar represents 100 mm.
Mean ± SEM is shown in (C).dependent manner. Particularly, in addition to cardiac specifica-
tion, Mesp1 also drives the specification of the hematopoietic
and skeletal myogenic lineages and marks precursors com-
mitted to these lineages. This observation not only redefines
the role of Mesp1 but also postulates a context-dependent
and dynamic nature of the Mesp1 transcriptional network.
EXPERIMENTAL PROCEDURES
Detailed experimental procedures can be found in the Supplemental Experi-
mental Procedures section.
Generation of Dox-Inducible Mesp1 Mouse ESC Line
The Dox-inducible Mesp1 ESC line was generated using the inducible
cassette-exchange strategy, as previously reported (Iacovino et al., 2011).
ESC Culture and Differentiation
ESCswere cultured and differentiated via EB formation into hematopoietic and
cardiac lineages using standard methods. The protocol for skeletal myogenic
differentiation is illustrated in Figure 5A.
Gene-Expression Analysis
Quantitative RT-PCRs were conducted using TaqMan probes (Applied Bio-
systems, Carlsbad, CA, USA) (Table S1).
Flow Cytometry Analysis
FACS analysis was performed using BD FACSAriaII (BD Biosciences, San
Diego, CA, USA). Antibodies used are listed in Table S2.
ChIP-PCR Analysis
ChIP was performed as described previously (Peng et al., 2009). The primer
pair for the Tal1 +40 kb enhancer was as follows: forward, 50-CGCCAA
GACCCTCTTCCTTAT-30; reverse, 50-CCAGCTGGTGCGTTATCAGTT-30.
Electrophoretic Mobility Shift Assay
Details about the electrophoretic mobility shift assay were described previ-
ously (Shi and Garry, 2010). The oligonucleotide harboring the E-box motif in
the Tal1 +40 kb enhancer is 50-CTGATAACGCACCAGCTGGGCCCCC
CACCA-30.
Mice
All animal procedures were performed according to the University of
Minnesota Institutional Animal Care and Use Committee guidelines and
approved protocols. Mesp1Cre/+ mice were obtained from Dr. Yumiko
Saga (through Dr. Kenneth Murphy). R26fl-stop-lacZ/fl-stop-lacZ (B6.129S4-
Gt(ROSA)26Sortm1Sor/J), R26fl-stop-EYFP/fl-stop-EYFP (B6.129X1-Gt(ROSA)
26Sortm1(EYFP)Cos/J), NOD scid gamma (NSG) (NOD.Cg-Prkdcscid Il2rgtm1Wjl/
SzJ), mdx4Cv (B6Ros.Cg-Dmdmdx-4Cv/J), and CD45.1/CD45.1 (CBy.SJL(B6)-
Ptprca/J) mice were obtained from Jackson Laboratories (Bar Harbor, ME,
USA). Pax7-ZsGreen mice were described previously (Bosnakovski et al.,
2008).
Bone Marrow Transplantation
Recipient NSG-CD45.1/CD45.1 mice (6 weeks old) were irradiated with
250 cGy 24 hr prior to transplantation. Total bone marrow cells were ob-
tained from femurs and tibia of Mesp1Cre/+;R26fl-stop-EYFP/+ mice. Both
EYFP+ and EYFP– fractions were sorted by FACS, and 150,000 cells were
injected into recipient mice intravenously. Peripheral blood samples
were analyzed by FACS at 4 weeks, 8 weeks, and 4 months after
transplantation.Mesp1-induced ESC-derived MHC+myotube. The red channel (MHC) and the
dicate that multiple DAPI+ nuclei are present in the same MHC+ myogenic cell
Cell Stem Cell 12, 587–601, May 2, 2013 ª2013 Elsevier Inc. 597
AC
D
E
B
Figure 6. Mesp1-Expressing Progenitors Contribute to the Adult Satellite Cell Pool
(A) FACS analysis of TA muscle from Pax7-ZsGreen mice confirming that more than 90% of Lin–a7-integrin+VCAM-1+ cells are ZsGreen+ (Pax7+).
(B) FACSprofiles showing the satellite cell-marker-gatedpopulation (Lin–a7-integrin+VCAM-1+) and the EYFPcontent thereof in the facialmuscles (far-left panels),
the masseter (middle-left panels), the diaphragm (middle-right panels), and the hindlimb muscles (far-right panels) of adult Mesp1Cre/+;R26fl-stop-EYFP/+ animals.
(C) Quantification of EYFP expression by FACS in satellite cell-marker-gated populations (left: Lin–a7-integrin+CD34+; right: Lin–a7-integrin+VCAM-1+) from
various muscle groups in adult Mesp1Cre/+;R26fl-stop-EYFP/+ animals (n = 4–5). Note that EYFP+ satellite cells are predominant in the facial muscles and masseter,
rare in the diaphragm and triceps, and almost undetectable in the back and hindlimb muscles.
(D) Immunostaining for MHC in EYFP+ sorted populations gated on satellite cell markers (Lin–a7-integrin+VCAM-1+) from various muscle groups. Multinucleated
MHC+myotubes coexpressing EYFP+ are observed in all sorted populations, indicating that the gated populations of Mesp1 origin are indeed skeletal myogenic
progenitors and not a nonmyogenic subpopulation. The scale bar represents 100 mm.
(legend continued on next page)
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NSG-mdx4Cv mice (4 months old) were subjected to a 1,200 cGy dose of
irradiation 2 days prior to satellite cell transplantation. Injury to TA muscle
was induced with the use of cardiotoxin one day later. EYFP+ satellite cells
(Lin–a7-integrin+VCAM-1+) isolated from the masseter or TA of Mesp1
Cre/+;
R26fl-stop-EYFP/+ mice were sorted and injected (2,500 cells from the
masseter and 200 cells from the TA) into the TA. Tissues were harvested
6 weeks later.
Statistical Analysis
Data are expressed as the mean ± SEM. Statistical significance was deter-
mined by Student’s t test and ANOVA as appropriate. Statistical significance
is set as p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.stem.2013.03.004.
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